Cocaine (COC) and methamphetamine (MTH) dependence have profound adverse medical, social and societal consequences. Medications development for these disorders is complicated by the fact that characteristics of COC and MTH addicts differ;the pharmacology of COC and MTH is similar, but not identical;and several agents demonstrating preliminary efficacy in COC users do not appear to be effective in MTH users. Because methodological issues may also be a factor in differential outcome, of importance is to examine medications in both COC and MTH dependent individuals in the same context. Thus, given that recent evidence suggests agents that decrease adrenergic activity may be effective in treating drug dependence, this proposal will examine the efficacy ofthe alphai- and beta-adrenergic antagonist carvedilol in delaying time to relapse in recently abstinent COC- and MTH-dependent individuals. This 12-wk, randomized, double blind, placebo-controlled clinical trial will provide treatment for 60 COC-dependent and 60 MTH-dependent (18-65 yrs) individuals over a five-year period. Participants first will reside at a residential facility (Recovery Centers of Arkansas) to initiate initial drug abstinence and be inducted on the study medication. They will be randomized by sex, severity of dependence, depressive/anxiety symptom severity and race to receive either placebo (N=30COC;N=30MTH), or carvedilol (50 mg/day;N=30COC; N=30MTH). Then participants transfer to the Outpatient Treatment Research Program and continue to receive study medication for weeks 3-12. During the outpatient portion ofthe trial, subjects participate in weekly individual cognitive behavioral therapy. During the trial, participants are given monetary incentives for complying with study requirements. At the end of 12 weeks, patients will be tapered off the study medication and referred to an appropriate treatment program. Efficacy will be determined by length of time in treatment, alleviation of withdrawal symptoms, length of time to lapse/relapse by self-report and urine toxicology, and psychosocial functioning. Prognostic relevance of factors such as sex, withdrawal symptoms, mood, genetic polymorphisms at the, e.g., alpha 1 receptor subtypes, and cognitive measures will be explored.

Public Health Relevance

This project will examine whether carvedilol prevents relapse relative to placebo in cocaine and/or methamphetamine dependent individuals. Findings of this study will not only shed light on whether carvedilol may improve upon treatment for psychostimulant dependence but also inform future medication development strategies for improving treatment for drug dependence disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA018197-10
Application #
8470149
Study Section
Special Emphasis Panel (ZDA1-SXC-E)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
10
Fiscal Year
2013
Total Cost
$225,559
Indirect Cost
$77,617
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Wachman, Elisha M; Hayes, Marie J; Lester, Barry M et al. (2014) Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr 165:472-8
Graham, David P; Nielsen, David A; Kosten, Thomas R et al. (2014) Examining the utility of using genotype and functional biology in a clinical pharmacology trial: pilot testing dopamine ?-hydroxylase, norepinephrine, and post-traumatic stress disorder. Psychiatr Genet 24:181-2
Spellicy, C J; Harding, M J; Hamon, S C et al. (2014) A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study. Genes Brain Behav 13:559-64
Mahoney 3rd, James J; De La Garza 2nd, Richard; Jackson, Brian J et al. (2014) The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. Psychiatry Res 219:367-71
Liu, Shijing; Green, Charles E; Lane, Scott D et al. (2014) The influence of dopamine ?-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study. Pharmacogenet Genomics 24:370-3
Mahoney 3rd, James J; Newton, Thomas F; Omar, Yasmine et al. (2013) The relationship between lifetime stress and addiction severity in cocaine-dependent participants. Eur Neuropsychopharmacol 23:351-7
Brewer 3rd, Alex J; Mahoney 3rd, James J; Nerumalla, Chandra S et al. (2013) The influence of smoking cigarettes on the high and desire for cocaine among active cocaine users. Pharmacol Biochem Behav 106:132-6
Kosten, Thomas R; Domingo, Coreen B; Hamon, Sara C et al. (2013) DBH gene as predictor of response in a cocaine vaccine clinical trial. Neurosci Lett 541:29-33
Haile, Colin N; Kosten, Thomas R (2013) Pharmacotherapy for stimulant-related disorders. Curr Psychiatry Rep 15:415
Ross, Elizabeth L; Yoon, Jin H; Mahoney 3rd, James J et al. (2013) The impact of self-reported life stress on current impulsivity in cocaine dependent adults. Prog Neuropsychopharmacol Biol Psychiatry 46:113-9

Showing the most recent 10 out of 39 publications